Quantitative Analysis of Diagnostic Guidelines for HER2-Status Assessment
- 1 May 2012
- journal article
- research article
- Published by Elsevier BV in The Journal of Molecular Diagnostics
- Vol. 14 (3), 199-205
- https://doi.org/10.1016/j.jmoldx.2012.01.012
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- What can the pathologist offer for optimal treatment choice?Annals of Oncology, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testingVirchows Archiv, 2010
- Emerging Technologies for Assessing HER2 AmplificationAmerican Journal of Clinical Pathology, 2009
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008
- The Equivocally AmplifiedHER2FISH Result on Breast Core BiopsyAmerican Journal of Clinical Pathology, 2008
- Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trialsBMC Cancer, 2007
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Testing for HER2 StatusOncology, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987